Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 4Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Gynecologic 2

Conditions

Ovarian Neoplasms 2Lung Neoplasms 2

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Pafolacianine × Clear all
NCT02872701 2023-03-24

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

On Target Laboratories, LLC

Phase 2 Completed
100 enrolled 15 charts
Thoracic

Lung Neoplasms

NCT04241315 2023-03-23

Elucidate

On Target Laboratories, LLC

Phase 3 Completed
112 enrolled 15 charts
Thoracic

Lung Neoplasms

NCT02317705 2022-06-21

Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer

On Target Laboratories, LLC

Phase 2 Completed
48 enrolled 10 charts
Gynecologic

Ovarian Neoplasms

NCT03180307 2022-02-04

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

On Target Laboratories, LLC

Phase 3 Completed
140 enrolled 11 charts 1 FDA
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡